DIBH Proton Planning
The overall objective is to estimate the actual or potential benefit of deep inspiration breath holding (DIBH) treatment in the context of proton radiotherapy as compared to 3 dimensional conformal radiation therapy (3DCRT) and intensity-modulated x-ray therapy (IMXT), as it relates to variability in tumor localization, treatment margins, target volume definition, doses to organs at risk and variations with treatment planning.
Checked against the public recordLast updated Mar 10, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age 18 and older * Biopsy-proven malignancy * The diagnosis of hepatocellular carcinoma may be made on a clinical basis without the need for a biopsy if the following criteria are met: a) Documentation of hepatitis B or C infection b)Liver mass with characteristic imaging (CT or MRI) features of hepatocellular carcinoma c) Alpha-feta protein (AFP) level greater than 20 ng/mL 3. Planned curative external beam RT as part of the patients treatment for the cancer diagnosis. * Subject must be cable of giving informed consent for standard external beam radiation therapy as well as for the study. * Subjects must be able to tolerate the deep inspiration breath hold (DIBH) training and procedures. Exclusion Criteria: * Subjects unsuitable for or unable to undergo definitive external beam, radiation therapy for their diagnosis of cancer * Subjects undergoing radiation with palliative (i.e., non-curative) intent. * Subjects unwilling to undergo simulation with the SpiroDynrX (SDX) system. * Subjects unable to hold their breath for a minimum of 10 seconds.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 10, 2020. Always confirm current availability with the study team.